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ServoventilationAbstract Background: Effective non-invasive ventilation (NIV) is dependent on optimal ventila-
tor settings for alveolar ventilation. Volume-assured pressure support (VAPS) is a mode of
servoventilation, providing constant automatic adjustment of pressure support (PS) to achieve a
target ventilation. Our aim is to evaluate the effectiveness of the new dual spontaneous mode of
ventilation named intelligent volume assured pressure support (iVAPS) in comparison with
conventional pressure support using S/T mode in-patients with acute hypercapnic respiratory
failure due to acute exacerbation of COPD.
Patients and methods: Forty patients with hypercapnic respiratory failure and respiratory acido-
sis due to acute exacerbation of COPD after failure of conventional medical treatment including
oxygen therapy were recruited into the study. Patients were categorized into two groups, Group
I ventilated with S/T mode and Group II ventilated with iVAPS mode. Patients were fitted with
an oronasal mask (Ultramirage, ResMed) connected to VPAP ST(ResMed).
Results: Both groups were comparable on admission. The successful outcome was achieved in
15 patients (75%) in the PS group vs 16 patients (80%) in the iVAPS group. Both groups show
significant (p< 0.01) improvement after 1 h NIV compared with preventilatory level in respiratory
rate (25.7 ± 1.6 vs 34.5 ± 1.8 for PS and 27.9 ± 4.8 vs 34.6 ± 1.3 for iVAPS) without significant
difference between the two groups. In the iVAPS group, there were a significantly (p< 0.01) higher
pH (7.34 ± 0.02 vs 7.31 ± 0.02 for PS group) and significantly (p< 0.001) lower PaCO2 (74.00
± 2.3 vs 79.00 ± 3.7 for PS group) after 1 h NIV. There was a significant (p< 0.01) higher minute
ventilation and significant (p< 0.001) lower peak inspiratory pressure in the iVAPS group after
1 h, and 6 h NIV.disease;
volume-
arterial
s partial
rculosis.
100 K. HusseinConclusion: Non invasive spontaneous dual ventilation using intelligent volume assured pressure
support (iVAPS) is characterized by stable alveolar ventilation with lower and variable inspiratory
pressure and earlier improvement of respiratory acidosis when compared with conventional
pressure support.
 2015 The Author. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Noninvasive ventilation (NIV) has gained increasing accep-
tance as a way to avoid intubation and improve outcomes in
selected patients with acute respiratory insufficiency [1].
Compared with optimum medical treatment plus oxygen
therapy, NIV can reduce duration of intensive care unit stay
and decrease complication in patients with chronic obstructive
pulmonary disease (COPD) exacerbations [2].
Prospective randomized controlled trials of the use of NIV
in acute exacerbation of COPD have been performed in a
variety of different locations and healthcare systems and in
patients with exacerbations of varying severity. A meta analy-
sis of these studies has shown more rapid improvements of in
respiratory rate and pH, a reduction in the need for intubation
and improved survival, reduced complications and length of
hospital stay [3].
Pressure support (PS) can assist spontaneous ventilation
and can be used in-patients with stable ventilatory require-
ments or during weaning. Once breath is initiated, pressure
rises rapidly to a preset plateau where it is held for the duration
of inspiration. The end of inspiration occurs when inspiratory
flow falls below a certain level, usually 25% of peak inspira-
tory flow [4]. In most new ventilators, there are different levels
of flow cycling that can be adjusted and not fixed. The patient
therefore determines respiratory frequency and timing of each
breath and if the patient fails to make respiratory effort, no
respiratory assistance will occur [5]. Tidal volume is variable
from breath to breath.
Volume assured pressure support (VAPS) is a new sponta-
neous dual mode using closed loop technique to obtain target
tidal volume or alveolar ventilation with variable pressure
support from breath to breath [6]. Two generations of VAPS
are developed: average volume assured pressure support
(AVAPS) with target tidal volume and variable pressure sup-
port; and intelligent volume assured pressure support (iVAPS)
with target alveolar ventilation (Va) and variable pressure
support.
In iVAPS, patients receive the minimum pressure required
to maintain optimal Va and hence it is called intelligent volume
assured pressure support [7].Objective
To evaluate the new dual spontaneous mode of ventilation
named intelligent volume assured pressure support (iVAPS)
in comparison with conventional pressure support using S/T
mode in-patients with acute hypercapnic respiratory failure
due to acute exacerbation of COPD.Patients and methods
The study was conducted from June 2013 to January 2015 at
Respiratory intensive care unit of Assiut university hospital.
Patients
Patients were offered enrollment into the study if they had
acute hypercapnic respiratory failure due to acute exacerbation
of COPD despite standard medical treatment including O2
therapy via venturi mask delivering FiO2 35% with worsening
dyspnea and at least one of the following: (1) pH <7.35 but
>7.10; (2) SpO2 <90%; (3) Respiratory rate >30 breath/min.
Patients were excluded if they met any of the following cri-
teria: shock (mean blood pressure <60 mmHg); upper airway
obstruction; facial trauma; bulbar paralysis; haemoptysis;
upper gastrointestinal bleeding; polycythemia; serum albumin
<30 gm/L; hypokalemia; severe underlying illness likely to
be terminal as hepatocellular or renal failure.
Patients were categorized into two groups, Group I venti-
lated with S/T mode and Group II ventilated with iVAPS
mode.
Initiation of non invasive ventilation (NIV)
Patients were fitted with oronasal mask (Ultramirage mask,
ResMed) connected to VPAP-ST(ResMed). Group I was
adjusted to S/T mode which is a combined mode; pressure sup-
port (S) and pressure control (Timed or T). PS was begun at an
expiratory pressure (EPAP) of 4 cm H2O and increased to
maximum 8 cm H2O according to PaCO2 level where increas-
ing EPAP help CO2 wash, and inspiratory pressure (IPAP) set
at a level that maintains IPAP – EPAP P8 cm H2O as a pres-
sure support. Then IPAP level was increased to maintain tidal
volume 8 ml/kg and O2 saturation >90%. We try to set IPAP
not more than 20 cm H2O to prevent gastric insufflation.
Timed mode (T) in S/T is a time triggered pressure limited,
time cycled mode (pressure controlled ventilation). This
ensures that patients will receive a minimum number of
breaths per minute in the event that the spontaneous breathing
rate drops below the rate setting. If the patient fails to initiate
an inspiration within the interval determined by rate control,
the unit triggers a timed breath resulting in a pressure con-
trolled (pressure limited, time cycled) breath at the Set IPAP
level (equal IPAP in S mode). The duration of each timed
breath is controlled by an inspiratory time control. Respira-
tory rate was set at 15 breaths/min.
Group II was adjusted to iVAPS mode. Adjust EPAP as in
Group I. iVAPS settings included height, patient target rate,
target alveolar ventilation (Va), minimum and maximum PS.
Table 1 Demographic and baseline parameters of both
groups.
Group I (20)
mean ± SD
Group II (20)
mean ± SD
P-value
Age (years) 60.80 ± 5.58 62.55 ± 4.85 NS
RR (breath/min) 34.10 ± 1.77 34.30 ± 1.34 NS
pH 7.23 ± 0.03 7.22 ± 0.02 NS
PaCO2(mmHg) 97.90 ± 7.76 97.10 ± 6.33 NS
PaO2(mmHg) 53.8 ± 5.48 55.9 ± 4.45 NS
Abbreviations: RR= respiratory rate; PaCO2 = partial pressure of
arterial carbon dioxide; PaO2 = partial pressure of arterial carbon
dioxide; NS = non significant.
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Figure 1 The outcome of both groups.
Non invasive spontaneous dual ventilation in patients with COPD 101Target rate is adjusted at 15 breath/min. Va was adjusted pro-
vided that tidal volume is 8 ml/kg of ideal body weight (IBW).
Minimum PS at 8 cm H2O, and maximum PS at 16 cm H2O.
In both modes, FiO2 was adjusted to maintain O2 satura-
tion P90%, trigger was adjusted at low set, cycle at high set,
Ti max at 2 sec, Ti min at 1 sec, and rise time at 200–300 ms.
Aerosolized bronchodilator therapy was delivered by tem-
porarily interrupting ventilatory assistance and using standard
nebulizers.
Monitoring of both groups
A strict observation and monitoring through the first hour of
initiation of NIV of the following:
1. Continuous monitoring of Heart rate, respiratory rate,
blood pressure, and SpO2.
2. ABG analysis: obtained by blood sample from radial artery
and analyzed using automated blood gas analyzer.
3. Mechanical parameters: Tidal volume (VT), minute ventila-
tion (VE), Peak inspiratory pressure (PIP), and respiratory
rate (RR).
4. Parameters specific for iVAPS: PS, and Va.
Follow up of these parameters at 6 h, 24 h and before dis-
continuation of NIV. Through this period of observation,
the presence of one major criterion was considered as an indi-
cation for immediate intubation while the presence of two
minor criteria at the end of first hour was considered to indi-
cate the need for intubation [8].
 Major criteria for intubation were: (a) Respiratory arrest,
(b) Haemodynamic instability with systolic pressure less
than 70 mmHg, and a heart rate of 50 beats/min or less,
and (c) Coma.
 Minor criteria of intubation were, (a) A respiratory rate
more than 35 breaths/min and higher than the value
recorded on admission, (b) An arterial pH 67.30 and lower
than the value recorded on admission, (c) A PaO2/FiO2 less
than 200 despite oxygen supplementation, and (d) Deterio-
ration of one or more points of the neurological scale of
Kelly and Matthay [9].
Outcome measures
Successful treatment was defined as objective improvement
during NIV, included the following changes from spontaneous
breathing: (1) pH >7.35, (2) Decrease in PaCO2 of >15–20%,
(3) SaO2 (with or without oxygen) ofP90%, (4) A decrease of
P20% in respiratory rate compared with spontaneous breath-
ing, and (5) Normal sensory state. Subjective criteria included
improvement of dyspnea and the patient’s comfort [10].
Failure is defined as the patient required intubation by ful-
fillment of one major criterion at any time or two minor crite-
ria after 1 h NIV.
Discontinuation of NIV
When clinical stability was achieved, which was defined as res-
piratory rate less than 24 breaths/min, a heart rate of 90 beats/
min, improved awareness, compensated normalized pH values,
with adequate SaO2 at low percentage of inspired O2 (3 l)[11].Statistical analysis
Statistical analysis was performed using Statistical Package for
the Social Sciences (SPSS-version 16). Results were given as a
mean ± SD for numerical data and as frequency using
chi-square test for nominal data. Groups were compared by
using t-test for numerical data (paired inside each group, and
unpaired to compare both groups at different points).
Differences were considered significant when p< 0.05.
Results
Forty patients were enrolled and included 20 patients in Group
I as well as 20 patients in Group II.
Demographic and baseline data of both groups are shown
in Table 1. There was no significant difference between the
two groups. The successful outcome was achieved in 15
patients (75%) in the PS group Vs 16 patients (80%) in the
VAPS group as shown in Fig. 1.
Fig. 2 shows follow up of respiratory rate in both groups. A
highly significant (p< 0.01) reduction of RR in both groups
after 1 h ventilation (from 34.5 ± 1.8 to 25.73 ± 1.6 in Group
I and from 34.6 ± 1.3 to 27.9 ± 4.8 in Group II) was noticed
and persisted up to 24 h ventilation in both groups. There was
no significant difference between the two groups at any point.
Gasometric parameters are demonstrated in Figs. 3–5. A
highly significant (p< 0.01) decrease of pH and increase of
PaCO2, and PaO2 after 1 h ventilation were observed in both
groups, with significantly (p< 0.01) higher pH and signifi-
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Figure 2 Follow up of respiratory rate in both successful groups
after 1 h, 6 h and 24 h of NIV.
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Figure 3 Follow up of pH in both successful groups after 1 h,
6 h and 24 h of NIV. * is statistical significant difference between
the two groups (p< 0.05).
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Figure 4 Follow up of PaCO2 in both successful groups after
1 h, 6 h and 24 h of NIV. * is statistical significant difference
between the two groups (p< 0.05).
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Figure 5 Follow up of PaO2 in both successful groups after 1 h,
6 h and 24 h of NIV.
Table 2 Follow up of minute ventilation in both successful
groups.
VE (L) Group I (n= 15) Group II (n= 16) P-value1
Mean ± SD Mean ± SD
1 h vent. 8.5 ± 1.8 10.1 ± 0.8 0.004
6 h vent. 8.0 ± 1.6 9.6 ± 0.7 0.001
P-value2 0.008 0.014
Abbreviations: VE = minute ventilation; P-value1 = statistically
significant difference between the two groups; P-value2 =
statistically significant difference between 1 h and 6 h ventilation in
each group.
Table 3 Follow up of peak inspiratory pressure in both
successful groups.
PIP (CmH2O) Group I (n= 15) Group II (n= 16) P-value
1
Mean ± SD Mean ± SD
1 h vent. 18.3 ± 1.3 15.0 ± 2.2 0.000
6 h vent. 18.3 ± 0.9 14.2 ± 1.7 0.000
P-value2 0.902 0.021
Abbreviations: PIP = Peak inspiratory pressure; P-value1 =
statistically significant difference between the two groups;
P-value2 = statistically significant difference between 1 h and 6 h
ventilation in each group.
102 K. Husseincantly (p< 0.001) lower PaCO2 in Group II after 1 h ventila-
tion and up to 24 h ventilation. No significant differences were
found in oxygenation between both groups at any time.
Mechanical parameters of both groups are compared in
Tables 2 and 3. There was a significant (p< 0.01) higher min-ute ventilation and significant (p< 0.001) lower peak inspira-
tory pressure in Group II after 1 h, and 6 h ventilation.
Fig. 6 shows a significant positive correlation between min-
ute ventilation and pH after 1 h ventilation in Group I (a)
(r= 0.798; and p= 0.000) and Group II (b) (r= 0.575; and
p= 0.008).
Discussion
Effective non-invasive ventilation is dependent on optimal ven-
tilator settings to maximize clinical benefit and patient toler-
ance. The proper use of NIV in appropriately chosen
patients with COPD can improve quality of life and increase
survival [12].
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Figure 6 Correlation between minute ventilation and pH after 1 h ventilation in Group I (a) and Group II (b) VE = minute ventilation;
r= correlation coefficient; p= significance.
Non invasive spontaneous dual ventilation in patients with COPD 103Intelligent volume-assured pressure support (iVAPS) is a
hybrid mode of servoventilation, providing automatic
adjustment of PS to achieve a target alveolar ventilation [7].
The results of our prospective randomized controlled trial
revealed that iVAPS, was not inferior to standard PS
ventilation regarding improvement of respiratory rate, pH,
hypercapnia, and oxygenation.
The first study that exists in the medical literature describ-
ing the benefits of using NIV with AVAPS in acute hypercap-
nic respiratory failure revealed statistically significant
differences in favor of the AVAPS group in consciousness,
PaCO2 and peak inspiratory positive airway pressure.
However, no significant differences in terms of length of stay
or days on NIV were observed [11].
Our results demonstrated a significantly higher pH and sig-
nificantly lower PaCO2 in the iVAPS group after 1 h ventila-
tion. This is consistent with Briones Claudett et al [11] who
revealed statistically significant differences in favor of the
AVAPS group in pH and, PaCO2. Oxygenation in our study
revealed no advantage of iVAPS mode and appreciate that
the main advantage of this dual mode is improvement of
alveolar ventilation and hence its indication in hypercapnicrespiratory failure. This is consistent with Briones Claudett
et al [10] who recorded a PaO2 of 83.1 ± 17.8 and 78
± 19.1 mmHg for ST and iVAPS groups respectively after
1 h NIV.
VAPS was studied for stable hypercapnic COPD patients in
a limited number of previous recent clinical trials. Ekkern-
kamp [13] compared non invasive iVAPS mode and high inten-
sity PS in forty patients and revealed that there was a greater
decrease in transcutaneous partial pressure of CO2 (PtCO2)
during iVAPS. On the other hand, other studies demonstrated
no advantage of AVAPS versus PS in chronic stable COPD
patients [14,15].
In chronic patients with obstructive sleep apnea and alveolar
hypoventilation syndrome, some authors reported a rapid
improvement in PaCO2 and sleep quality using VAPS [16,17]
while others reported no difference between AVAPS and PS [6].
As regards mechanical parameters, our results demon-
strated that minute ventilation is higher and more stable (as
deduced from lower standard deviation) in the iVAPS group.
Minute ventilation is positively correlated to pH and this illus-
trates the greater improvement of respiratory acidosis in the
iVAPS group.
104 K. HusseinPeak inspiratory pressure is significantly lower and more
variable (as deduced from higher standard deviation) in the
iVAPS group. This variability is due to variable PS from
breath to breath and hence lower total pressure than fixed level
recorded in the PS group. In a recent study comparing iVAPS
with standard PS, iVAPS was as effective as standard PS with
significantly (p= 0.001) lower median PS [7]. Also, Briones
Claudett et al [11] recorded a statistically significant reduction
of peak inspiratory pressure in the AVAPS group (p= 0.005).
Conclusion
Non invasive spontaneous dual ventilation using intelligent
volume assured pressure support (iVAPS) is characterized by
stable alveolar ventilation with lower and variable inspiratory
pressure and earlier improvement of respiratory acidosis when
compared with conventional pressure support.
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